Unlock Insights into Stroke Research | Specialized Experimental Model Solutions

Ace Therapeutics' Collagenase-Induced ICH Model offers a robust, reproducible, and pathophysiologically relevant platform to accelerate preclinical ICH research and therapeutic development. This brochure provides a comprehensive overview of our collagenase-induced ICH model, detailing how it supports mechanistic studies and translational drug evaluation across multiple stages of hemorrhagic stroke research.

A Gold-Standard Model for Hemorrhagic Stroke

• Progressive hematoma formation that more closely mimics spontaneous human ICH than whole-blood injection models
• Highly reproducible lesion size and location, enabling consistent and interpretable outcomes
• Tunable injury severity, allowing modeling of mild to severe hemorrhage through collagenase dose adjustment .

Capturing Secondary Brain Injury Mechanisms

• Robust perihematomal edema and neuroinflammatory responses
• Modeling of ischemic penumbra and secondary tissue damage
• Ideal for evaluating neuroprotective, anti-inflammatory, and edema-reducing therapies

Comprehensive Functional and Pathological Readouts

• Neurological and behavioral assessments to quantify functional impairment
• Sensorimotor tests including placement and corner turn assays
• Brain water content analysis for objective measurement of cerebral edema

Designed for Translational ICH Drug Development

Ace Therapeutics' collagenase-induced ICH model supports a wide range of research and development objectives, including:

• Pathogenesis and mechanism-of-action studies in hemorrhagic stroke
• Preclinical efficacy testing of small molecules, biologics, and cell-based therapies
• Investigation of post-ICH inflammation, edema, and multi-organ dysfunction

Discover how the Ace Therapeutics Collagenase-Induced ICH Model can help you generate meaningful, decision-driving preclinical data in hemorrhagic stroke research.

You might be interested in...